Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Misses Estimates By $0.26 EPS

Theravance Biopharma (NASDAQ:TBPH) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26), Zacks reports. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.

Theravance Biopharma Price Performance

NASDAQ:TBPH traded up $0.11 during trading hours on Wednesday, reaching $9.08. 276,927 shares of the company traded hands, compared to its average volume of 205,984. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $10.90. The stock has a market cap of $446.50 million, a P/E ratio of -8.99 and a beta of 0.21. The firm’s 50-day moving average is $9.36 and its 200-day moving average is $8.91.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.75.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.